|
Anon., «54,404 ADRs filed in US in 1987», Scrip, No 1318, 17 Jun 1988, p21; Kaur, N., «Overprescription: doctors profit, patients suffer», Utusan Konsumer, mid-Jan 1992, p5; Lexchin, op cit. |
|
|
Fletcher, A.P., «Spontaneous adverse drug reaction reporting vs event monitoring: a comparison», Journal of the Royal Society of Medicine, Vol 84, Jun 1991, pp341-4. |
|
|
IFPMA, IFPMA Code of Pharmaceutical Marketing Practices, Geneva, IFPMA, 1989, p4. |
|
|
Medawar, C., The Wrong Kind of Medicine?, London, Consumers’ Association and Hodder & Stoughton, 1984, pp45-6. |
|
|
Abrahams, P., «Discovering healthy profits», Financial Times, 10 Dec 1991, Section III, ðIII. |
|
|
WHO, Clinical Pharmacological Evaluation in Drug Control, EUR/ICP/DSE 173, Copenhagen, WHO, 1993. |
|
|
Schwartz, H., «Improving the industry’s image», Scrip, No 1620/21, 29/31 May 1991, pp22-3. |
|
|
Anon., «Drug use problems in Latin America», Scrip, No 1683, 15 Jan 1992, p28. |
|
|
Anon., «Pharmaceutical misuse costs Iran $100 mill pa». Scrip, No 1787, 19 Jan 1993, p13. |
|
|
Fabricant, S.J. and Hirschhorn, N., «Deranged distribution, perverse prescription, unprotected use: the irrationality of pharmaceuticals in the developing world», Health Policy and Planning, Vol 2, No 3, 1987, pp204-13; WHO, The World Drug Situation, Geneva, WHO, 1988. |
|
|
Ballen, K., «America’s most admired corporations», Fortune, 10 Feb 1992, ðð30-4. |
|
|
Anon., «US promotion criticised», Scrip, No 1577/8, 21/26 Dec 1990, pp16-17. |
|
|
Anon., «FDA’s drug promotion problems», Scrip, No 1389, 24 Feb 1989, p14. |
|
|
Anon., «FDA warns industry on promotion», Scrip, No 1611, 26 Apr 1991, p17. |
|
|
Chetley, A. and Mintzes, B. (eds), Promoting Health or Pushing Drugs?, Amsterdam, HAI, 1992, pp12-15. |
|
|
Health and Public Policy Committee of the American College of Physicians, «Improving medical education in therapeutics», Annals of Internal Medicine, Vol 108, No 1, Jan 1988, pp145-7. |
|
|
Grant, R., Which? Medicine, London, Consumers Association and Hodder & Stoughton, 1992, p58. |
|
|
Position paper entitled «Physicians and the Pharmaceutical Industry», quoted in: Schwartz, H., «Are pharmaceutical companies bribing doctors? - the Schwartz commentary», Scrip, No 1515, 18 May 1990, p22. |
|
|
Anon., «When drug labels cry wolf», The Economist, 12 Oct 1985, p96. |
|
|
Ibid |
|
|
Steele, R.W. and Kearns, G.L., «Antimicrobial therapy for paediatric patients», Pediatric Clinics of North America, Vol 36, No 5, Oct 1989, pp1321-49. |
|
|
Lynn, M., The Billion Dollar Battle: Merck v Glaxo, London, Mandarin, 1992, p128. — 16 —
|